Ocular Therapeutix (OCUL) Competitors $8.78 -0.14 (-1.57%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends OCUL vs. KNSA, INVA, ARQT, SUPN, PLRX, LNTH, RNA, CRNX, KRYS, and ADMAShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Kiniksa Pharmaceuticals (KNSA), Innoviva (INVA), Arcutis Biotherapeutics (ARQT), Supernus Pharmaceuticals (SUPN), Pliant Therapeutics (PLRX), Lantheus (LNTH), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), and ADMA Biologics (ADMA). These companies are all part of the "medical" sector. Ocular Therapeutix vs. Kiniksa Pharmaceuticals Innoviva Arcutis Biotherapeutics Supernus Pharmaceuticals Pliant Therapeutics Lantheus Avidity Biosciences Crinetics Pharmaceuticals Krystal Biotech ADMA Biologics Ocular Therapeutix (NASDAQ:OCUL) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership. Do institutionals and insiders believe in OCUL or KNSA? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 3.5% of Ocular Therapeutix shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend OCUL or KNSA? Ocular Therapeutix currently has a consensus price target of $16.71, suggesting a potential upside of 90.37%. Kiniksa Pharmaceuticals has a consensus price target of $36.60, suggesting a potential upside of 72.56%. Given Ocular Therapeutix's higher possible upside, research analysts clearly believe Ocular Therapeutix is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor OCUL or KNSA? Ocular Therapeutix received 266 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 70.10% of users gave Ocular Therapeutix an outperform vote while only 64.89% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOcular TherapeutixOutperform Votes43670.10% Underperform Votes18629.90% Kiniksa PharmaceuticalsOutperform Votes17064.89% Underperform Votes9235.11% Which has more volatility & risk, OCUL or KNSA? Ocular Therapeutix has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Is OCUL or KNSA more profitable? Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Ocular Therapeutix's net margin of -283.74%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-283.74% -45.18% -30.87% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% Does the media prefer OCUL or KNSA? In the previous week, Ocular Therapeutix had 13 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 13 mentions for Ocular Therapeutix and 0 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 0.49 beat Ocular Therapeutix's score of 0.40 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Ocular Therapeutix Neutral Kiniksa Pharmaceuticals Neutral Which has better valuation & earnings, OCUL or KNSA? Kiniksa Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$58.44M23.62-$80.74M-$1.32-6.65Kiniksa Pharmaceuticals$270.26M5.67$14.08M-$0.14-151.49 SummaryOcular Therapeutix and Kiniksa Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.40B$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-6.654.8587.8613.46Price / Sales23.62374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book3.9210.216.946.30Net Income-$80.74M$153.61M$119.12M$225.93M7 Day Performance-11.49%-2.00%-1.84%-1.32%1 Month Performance-22.78%-7.47%-3.65%0.60%1 Year Performance300.91%31.80%31.64%26.23% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix3.7464 of 5 stars$8.78-1.6%$16.71+90.4%+273.6%$1.40B$58.44M-6.65267KNSAKiniksa Pharmaceuticals1.9939 of 5 stars$21.21+1.9%$36.60+72.6%+33.9%$1.50B$270.26M0.00220INVAInnoviva1.2975 of 5 stars$19.15+0.3%N/A+40.6%$1.20B$310.46M27.75112News CoverageHigh Trading VolumeARQTArcutis Biotherapeutics1.7417 of 5 stars$10.18+0.9%$15.50+52.3%+391.8%$1.18B$59.61M0.00150SUPNSupernus Pharmaceuticals2.3042 of 5 stars$36.12+1.7%$36.00-0.3%+32.3%$1.96B$607.52M33.76580Positive NewsPLRXPliant Therapeutics3.4847 of 5 stars$12.73-0.5%$40.57+218.7%-11.4%$778.32M$1.58M0.0090LNTHLantheus4.5969 of 5 stars$86.45+8.8%$122.50+41.7%+25.1%$5.52B$1.30B14.38834Positive NewsGap UpRNAAvidity Biosciences2.3883 of 5 stars$43.65+0.9%$63.22+44.8%+631.2%$5.16B$9.56M0.00190Insider TradeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.5524 of 5 stars$56.07+1.6%$70.18+25.2%+85.5%$5.12B$4.01M0.00210Analyst RevisionKRYSKrystal Biotech4.8348 of 5 stars$178.10+0.1%$202.29+13.6%+70.0%$5.12B$50.70M100.62229Positive NewsADMAADMA Biologics3.3177 of 5 stars$21.37+3.6%$21.25-0.6%+430.3%$4.88B$258.21M76.32530 Related Companies and Tools Related Companies KNSA Competitors INVA Competitors ARQT Competitors SUPN Competitors PLRX Competitors LNTH Competitors RNA Competitors CRNX Competitors KRYS Competitors ADMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCUL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
